Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.1K
Tumor Progression02:07

Tumor Progression

6.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K
Long-term Potentiation01:35

Long-term Potentiation

56.8K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
56.8K
Long-term Potentiation01:25

Long-term Potentiation

3.0K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
3.0K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond dissemination criteria: lesion-based longitudinal MRI of atypical demyelinating lesions at the boundary of multiple sclerosis.

Journal of neurology·2026
Same author

Nanofiber-based platform for quantitative analysis of human oligodendrocyte ensheathment with pharmacological perturbations.

Stem cell reports·2026
Same author

MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trial.

JHEP reports : innovation in hepatology·2026
Same author

Dissecting microglial contributions to neurodegenerative disease pathophysiology using human pluripotent stem cells.

Stem cell reports·2026
Same author

Apolipoprotein E Deficiency Impairs Human Microglial Proliferation Accompanied by Elevated Cellular Oxidative Stress.

Journal of cellular and molecular medicine·2026
Same author

Protocol for measuring lipid membrane fluidity in human iPSC-derived neural cells.

STAR protocols·2026
Same journal

[Neuropathological Autopsies in Japan: Current Scenario and Challenges].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Telemedicine and Digital Technologies in Neurological Intractable Diseases].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Disaster Countermeasures for Intractable Neurological Disease].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Supporting Health Care Transition for Patients with Childhood-Onset Chronic Conditions: Within Intractable Disease Care in Japan].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Multidisciplinary Collaboration between Hospitals and Clinics at the University Hospital and the Core Hospital for the Treatment of Intractable Diseases].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[The Role of Coordinators for Intractable Diseases in Japan].

Brain and nerve = Shinkei kenkyu no shinpo·2026
See all related articles

Related Experiment Video

Updated: Nov 5, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.3K

[Secondary Progressive Multiple Sclerosis].

Mio Hamatani1, Takayuki Kondo

  • 1Department of Neurology, Kansai Medical University Medical Center.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|May 19, 2021
PubMed
Summary
This summary is machine-generated.

Secondary progressive multiple sclerosis (SPMS) involves progressive neurological decline. Understanding its complex mechanisms, including inflammation and glial dysfunction, is crucial for developing effective SPMS treatments.

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.3K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.4K

Related Experiment Videos

Last Updated: Nov 5, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.3K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.3K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.4K

Area of Science:

  • Neuroimmunology
  • Neurology
  • Pathogenesis of Multiple Sclerosis

Background:

  • Secondary progressive multiple sclerosis (SPMS) is characterized by relentless clinical deterioration, distinct from relapsing-remitting courses.
  • Diagnosing SPMS presents challenges due to the absence of definitive diagnostic markers and reliance on retrospective evaluation.
  • Current understanding of SPMS pathogenesis is limited, with few effective therapeutic options available.

Purpose of the Study:

  • To elucidate the underlying pathogenic mechanisms driving neurodegeneration in SPMS.
  • To identify potential therapeutic targets for managing SPMS progression.

Main Methods:

  • Review and synthesis of current research on SPMS pathophysiology.
  • Analysis of proposed mechanisms including chronic inflammation, immune cell involvement (T and B cells), glial dysfunction, and mitochondrial issues.

Main Results:

  • SPMS neurodegeneration is hypothesized to stem from chronic inflammation, compartmentalized immune cells, and impaired glial and mitochondrial function.
  • Gait disturbance is a primary, though not sole, clinically evaluated symptom.

Conclusions:

  • Novel therapeutic strategies for SPMS should focus on neuroprotection, remyelination promotion, and immunomodulation.
  • Further research into SPMS pathogenesis is essential for advancing treatment paradigms.